 |
3 Products |  |
9 Diseases | | 3 Products |
|
0 Trials |  |
34 News |  |
- | ropivacaine depot (F-93) / Encore, PainReform
Journal: Juvenile Reactive Arthritis and other Spondyloarthritides of Childhood: A 28-year Experience from India. (Pubmed Central) - Feb 8, 2022
101 ERA [M:F-93:7; age-16(14-20) years] had a longer disease duration (45 vs 2.75 months, p<0.001), as compared with jReA...jUSpA (n=17) had a similar clinico-laboratory profile and exhibited significant (7 of 17, 58.3%) chronicity over 9.5(4.8-37) months follow-up. jReA and jSpA exhibit similar features apart from varying disease duration, suggesting that jspA may form a continuum with similar clinico-laboratory profiles plausibly due to shared pathogenesis.
- | Impoyz (clobetasol) / Encore
Enrollment change, Trial completion date, Trial termination: Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 (clinicaltrials.gov) - Sep 14, 2020
P2, N=22, Terminated, Sponsor: Encore Dermatology, Inc.
jReA and jSpA exhibit similar features apart from varying disease duration, suggesting that jspA may form a continuum with similar clinico-laboratory profiles plausibly due to shared pathogenesis. N=50 --> 22 | Trial completion date: Jun 2019 --> Jun 2020 | Recruiting --> Terminated; Difficulty in enrollment
- || DFD-06 / Dr. Reddy’s
Metallica cancel Australia, New Zealand tour as Hetfield enters rehab https://t.co/7rDdFD06jZ (Twitter) - Sep 27, 2019
- | Impoyz (clobetasol) / Encore
Trial completion date, Trial primary completion date: Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 (clinicaltrials.gov) - Feb 15, 2019
P2, N=50, Recruiting, Sponsor: Encore Dermatology, Inc.
N=50 --> 22 | Trial completion date: Jun 2019 --> Jun 2020 | Recruiting --> Terminated; Difficulty in enrollment Trial completion date: May 2018 --> Jun 2019 | Trial primary completion date: May 2018 --> Jun 2019
- | ropivacaine depot (F-93) / Encore, PainReform
Journal: Targeted degradation of BET proteins in triple-negative breast cancer. (Pubmed Central) - Sep 14, 2017
In multiple murine xenograft models of human breast cancer, BETd-246 and a further optimized analogue BETd-260 effectively depleted BET proteins in tumors and exhibited strong antitumor activities at well-tolerated dosing schedules. Overall, our findings show how specific targeting of BET proteins for degradation yields an effective therapeutic strategy for TNBC treatment.
- | Impoyz (clobetasol) / Encore
New P2 trial: Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 (clinicaltrials.gov) - Jun 7, 2017
P2, N=50, Recruiting, Sponsor: Promius Pharma, LLC
- Impoyz (clobetasol) / Encore
Trial primary completion date: DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Sep 27, 2016
P2, N=50, Completed, Sponsor: Promius Pharma, LLC
Overall, our findings show how specific targeting of BET proteins for degradation yields an effective therapeutic strategy for TNBC treatment. Trial primary completion date: Aug 2015 --> Apr 2016
- ||||||| Impoyz (clobetasol) / Encore
Trial completion: A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Aug 3, 2016
P3, N=265, Completed, Sponsor: Promius Pharma, LLC
Trial primary completion date: Aug 2015 --> Apr 2016 Active, not recruiting --> Completed
- | Impoyz (clobetasol) / Encore
Trial completion: DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Aug 3, 2016
P2, N=50, Completed, Sponsor: Promius Pharma, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Impoyz (clobetasol) / Encore
Trial completion: A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Aug 3, 2016
P3, N=267, Completed, Sponsor: Promius Pharma, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Impoyz (clobetasol) / Encore
Enrollment closed: A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 18, 2016
P3, N=265, Active, not recruiting, Sponsor: Promius Pharma, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Impoyz (clobetasol) / Encore
Enrollment closed: A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 18, 2016
P3, N=267, Active, not recruiting, Sponsor: Promius Pharma, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Impoyz (clobetasol) / Encore
Enrollment open: A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Jan 16, 2016
P3, N=264, Recruiting, Sponsor: Promius Pharma, LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Impoyz (clobetasol) / Encore
New P3 trial: A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Dec 18, 2015
P3, N=264, Not yet recruiting, Sponsor: Promius Pharma, LLC
- |||||| Impoyz (clobetasol) / Encore
Enrollment open, Trial primary completion date: A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Dec 11, 2015
P3, N=264, Recruiting, Sponsor: Promius Pharma, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2015 --> Jun 2016
- | Impoyz (clobetasol) / Encore
Enrollment closed: DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Sep 28, 2015
P2, N=50, Active, not recruiting, Sponsor: Promius Pharma, LLC
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- ||||| Impoyz (clobetasol) / Encore
Trial initiation date: A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Sep 28, 2015
P3, N=264, Not yet recruiting, Sponsor: Promius Pharma, LLC
Recruiting --> Active, not recruiting Initiation date: May 2015 --> Oct 2015
- flurbiprofen / Generic mfg.
Trial completion, Trial primary completion date: Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy Subjects (clinicaltrials.gov) - Sep 14, 2015
P1, N=16, Completed, Sponsor: Gerd Geisslinger
Initiation date: May 2015 --> Oct 2015 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014
- |||||||||| Impoyz (clobetasol) / Encore
New P3 trial: A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 15, 2015
P3, N=264, Not yet recruiting, Sponsor: Promius Pharma, LLC
- Impoyz (clobetasol) / Encore
Trial primary completion date: DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Apr 30, 2015
P2, N=50, Recruiting, Sponsor: Promius Pharma, LLC
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014 Trial primary completion date: Jan 2015 --> Aug 2015
- flurbiprofen / Generic mfg.
Enrollment open: Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy Subjects (clinicaltrials.gov) - Aug 12, 2014
P1, N=16, Recruiting, Sponsor: Gerd Geisslinger
Trial primary completion date: Jan 2015 --> Aug 2015 Active, not recruiting --> Recruiting
- flurbiprofen / Generic mfg.
New P1 trial: Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy Subjects (clinicaltrials.gov) - Aug 1, 2014
P1, N=16, Active, not recruiting, Sponsor: Gerd Geisslinger
- | Impoyz (clobetasol) / Encore
New P2 trial: DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 4, 2014
P2, N=50, Recruiting, Sponsor: Promius Pharma, LLC